Evolus (NASDAQ:EOLS) achieved Q2 revenue of $49.3M, growing 33% Y/Y and 10 percentage points above Q1 2023.
The company also raised FY 2023 net revenue guidance to $185M-195M from $180M-190M.
The company showed record growth and all-time highs in new accounts and consumer loyalty enrollments and redemptions.
David Moatazedi, President and CEO, “As we announced in May, we are extremely excited to expand our product portfolio to include a line of five different fillers beginning in 2025, clearly leveraging our strong distribution model and loyalty programs, and accelerating our top-line growth to $700 million by 2028.”
Q2 results will be out on Wednesday, August 2, 2023.
More on Evolus:
-
Evolus: Botox Copy Cat In A Challenging Aesthetic Market
-
Evolus: Capitalizing On The Growth Of Aesthetics Market
